Patient enrollment is an element of the clinical study over which Cardiogenics has very limited control, thus foolish for the Company to identify a specific date for completion of the trial. If the company has sufficient data on likely patient enrollment rates, Cardiogenics could make a qualifying statement that if enrollment continues as they have experienced or complies with predictive enrollment rates then the last patient is projected to be enrolled in the study within some number of weeks or some specific future month."

As of 2:00 PM EST December 2012 CardioGenics has not announced the results of the Beta Site Study. As the Company publicly stated enrollment would take no more than 12 weeks (a mid-November date) we shareholders must conclude the "enrollment data" on which the Company based its projected enrollment rates was flawed.

Hopefully Dr. G and the BoD will recogize their fiduciary responsibilty and inform the investment community of the status of the Beta Site Study. Two things I would like to know are

1. how many patients are fully enrolled, and
2. what actions has the company taken to increase the enrollment rate.

I have attempted to discover the answers to these two questions but have been unsuccessful. What I have been able to confirm through a number of contacts within Wayne State University affiliated hospitals is that patients are continuing to be enrolled in the Beta Site Study.

So with this post I bid you adieu as my wife and I depart our boat slip at daybreak and will be cruising off the Eastern Seaboard for the next several weeks.

I wish you all a great holiday season and a successful New Year (especially those of you who own shares of CGNH)!